Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy

Cancer statistics, 2017

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2017 · 15K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.5K citations

Medicine, Oncology, Pharmacology +16

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Yuankai Shi, Joseph S. K. Au, Sumitra Thongprasert et al. · Journal of Thoracic Oncology · 2014 · 1.6K citations · Full text

Medicine, Genetics, Oncology +14

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

James Chih‐Hsin Yang, Lecia V. Sequist, Sarayut Lucien Geater et al. · The Lancet Oncology · 2015 · 982 citations

Medicine, Oncology, Pharmacology +16

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Jenn‐Yu Wu, Chong‐Jen Yu, Yeun‐Chung Chang et al. · Clinical Cancer Research · 2011 · 466 citations · Full text

Medicine, Oncology, Pharmacology +14